GlassScriptPhysician profile
Roger D Ridgeway
NPI 1427219799
$5,857.85
in general payments reported to CMS, 2019-2025
25 companies · $73.41 in 2025
The $73.41 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $997 · 2020: $799 · 2021: $1,493 · 2022: $1,355 · 2023: $1,110 · 2024: $29.17 · 2025: $73.41.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,174 · Education: $38.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,174.49 |
| Education | $38.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,094.49 | 2021-2025 | |
| Lundbeck LLC | $876.57 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $616.30 | 2020-2023 | |
| Allergan, INC. | $564.23 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $537.51 | 2019-2023 | Rexulti, Abilify Maintena |
| Takeda Pharmaceuticals U.S.A., INC. | $532.88 | 2019-2023 | Trintellix |
| Teva Pharmaceuticals USA, INC. | $354.34 | 2019-2023 | Austedo, Austedo Xr |
| Vanda Pharmaceuticals INC. | $271.62 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $168.21 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $142.31 | 2021 | |
| Eisai INC. | $128.26 | 2020-2021 | |
| Almatica Pharma LLC | $98.20 | 2022-2023 | Loreev Xr |
| Alkermes, INC. | $91.70 | 2021-2023 | Aristada, Lybalvi |
| Axsome Therapeutics, INC. | $77.00 | 2022-2023 | Auvelity |
| Idorsia Pharmaceuticals US INC | $70.76 | 2022-2023 | Quviviq |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $44.90 | 2022 | |
| Shire North American Group INC | $40.58 | 2019 | |
| Avanir Pharmaceuticals, INC. | $35.81 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $21.93 | 2022 | |
| Jazz Pharmaceuticals INC. | $18.09 | 2022 | |
| Neurocrine Biosciences, INC. | $17.66 | 2021 | |
| Bausch Health US, LLC | $15.50 | 2022 | |
| Noven Therapeutics, LLC | $14.19 | 2021 | |
| Neuronetics, INC. | $13.04 | 2019 | |
| Adlon Therapeutics L.P. | $11.77 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roger Ridgeway listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.